









Markets
/
Stocks
/
nasdaq-ctkb
/

Cytek Biosciences Inc

CTKB

4.090USD

+0.170+4.34%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

520.19MMarket Cap

LossP/E TTM



Cytek Biosciences Inc

4.090

+0.170+4.34%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

91 / 207

Overall Ranking

231 / 4721

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 5 analysts

Buy

Current Rating

5.125

Target Price

+30.74%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its Full Spectrum Profiling (FSP) technology. Its FSP platform includes its core instruments, the Cytek Aurora and Northern Lights systems; its cell sorter, the Cytek Aurora CS; the Cytek Orion reagent cocktail preparation system; the flow cytometer and imaging products under the Amnis and Guava brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Cytek Northern Lights systems are flow cytometers that deliver high-resolution, high-content, and high-sensitivity cell analysis. Its Cytek Aurora CS is a cell sorter that leverages the detection and sensitivity capabilities of its FSP technology to isolate living cell populations from lower to higher complexity panels beyond 40 biomarkers.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 22.20% year-on-year.

Fairly Valued

The company’s latest PE is -77.76, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 88.51M shares, decreasing 10.46% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 7.74M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 7.77, which is higher than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 45.60M, representing a year-over-year decrease of 2.18%, while its net profit experienced a year-over-year decrease of 46.49%.

Score

Industry at a Glance

Previous score

7.77

Change



Financials

9.69

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.60

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

9.15

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.19

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.22

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 1.20, which is lower than the Healthcare Equipment & Supplies industry's average of 2.00. Its current P/E ratio is -74.52, which is -20.87% below the recent high of -58.97 and -51.10% above the recent low of -112.61.

Score

Industry at a Glance

Previous score

1.20

Change

1.6

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 91/207

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

The company’s current earnings forecast score is 7.20, which is lower than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for Cytek Biosciences Inc is 4.25, with a high of 8.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

7.20

Change

Support & Resistance

No Data

Analyst Rating

Based on 5 analysts

Buy

Current Rating

5.125

Target Price

+30.74%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Cytek Biosciences Inc

CTKB

Boston Scientific Corp

BSX

Edwards Lifesciences Corp

Intuitive Surgical Inc

ISRG

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 5.96, which is lower than the Healthcare Equipment & Supplies industry's average of 6.45. Sideways: Currently, the stock price is trading between the resistance level at 4.22 and the support level at 3.67, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.96

Change

0.4

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

-0.038

Neutral

RSI(14)

54.818

Neutral

STOCH(KDJ)(9,3,3)

59.245

Buy

ATR(14)

0.214

High Vlolatility

CCI(14)

78.917

Neutral

Williams %R

23.711

Buy

TRIX(12,20)

0.044

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

3.962

Buy

MA10

3.973

Buy

MA20

4.025

Buy

MA50

3.812

Buy

MA100

3.515

Buy

MA200

4.364

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 5.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 69.57%, representing a quarter-over-quarter decrease of 2.50%. The largest institutional shareholder is The Vanguard, holding a total of 7.74M shares, representing 6.08% of shares outstanding, with 32.77% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

16.50M

-1.99%

The Vanguard Group, Inc.

Star Investors

9.60M

-17.92%

Brown Capital Management, LLC

7.46M

-9.49%

HHLR Advisors, Ltd.

6.66M

Yan (Ming)

6.04M

+0.17%

Jiang (Wenbin)

5.26M

+0.70%

Topline Capital Management, LLC

1.47M

+521.64%

State Street Global Advisors (US)

4.38M

-2.84%

Dimensional Fund Advisors, L.P.

2.85M

+55.91%

Geode Capital Management, L.L.C.

2.69M

+1.80%

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 3.11, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 1.35. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.